---
title: "Lysergide (DT120) in Generalized anxiety disorder: Cost-effectiveness evidence"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Cost-effectiveness evidence. Topics: Summary: sponsor price and revenue statements, Summary: monitoring-session coding and costs, Summary: analog economic evaluations, Summary: population and burden inputs, and 13 further topics. 17 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics/cost-effectiveness"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Cost-effectiveness evidence

<a id="heading-4.1"></a>

## 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

### Summary: sponsor price and revenue statements

The sponsor states that the price of DT120 ODT has not been established. On its third quarter 2026 earnings call, the sponsor stated a commercial pricing corridor of $30,000 to $75,000 per treatment course, based on preliminary feedback from payers on the interventional psychiatry market, and said the corridor would narrow with further payer discussions. In the sponsor's 2026 Investor and Analyst Day presentation, payers name Spravato as the primary price analog, expect FDA-approved psychedelic treatments to be covered, and expect to manage use with prior authorization. The sponsor's 2026 corporate presentation combines 2 patients per month (24 per year), ~4,000 interventional psychiatry clinics (about half of the estimated Spravato REMS sites), and 100K patients treated into a $5B potential gross revenue opportunity, assuming the midpoint of the Spravato surrogate pricing range.

Source: [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110); [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-4.1-2"></a>

### Summary: monitoring-session coding and costs

The sponsor describes a single-visit model reimbursed for the full session; each pivotal dosing session requires 8 hours of monitoring and clearance of the end-of-session checklist, and the sponsor states that existing coding systems could potentially be applied or changed, with reimbursement and coding not yet established. CPT codes 0820T, 0821T, and 0822T describe continuous in-person monitoring and intervention during psychedelic medication therapy, each hour, by a first physician or other qualified health care professional, a concurrent second one, and clinical staff under the direction of a physician or other qualified health care professional. For esketamine, CMS created HCPCS codes G2082 and G2083, effective January 1, 2020 on an interim final basis; G2082 covers an office visit with up to 56 mg of esketamine and 2 hours of post-administration observation, with supply inputs priced at $590.02 for 56 mg and $885.02 for 84 mg.

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [BrainFutures CPT and HCPCS coding guide (2023)](https://www.brainfutures.org/wp-content/uploads/2023/09/A-Guide-to-CPT-and-HCPCS-Codes-for-Psychedelic-Assisted-Therapy_Charts.pdf); [CMS CY 2020 Physician Fee Schedule final rule (2019)](https://www.federalregister.gov/documents/2019/11/15/2019-24086/medicare-program-cy-2020-revisions-to-payment-policies-under-the-physician-fee-schedule-and-other-changes-to-part)

<a id="topic-4.1-3"></a>

### Summary: analog economic evaluations

ICER's esketamine report used a base-case price of $295 per 28 mg device, estimated an incremental cost-effectiveness ratio of approximately $198,000 per QALY versus no additional treatment, assigned a CPT 99214 visit to each dose for the 2-hour observation, and estimated that 16% of eligible patients could be treated at list price within its $819 million threshold. A separate cost-effectiveness analysis attributed most of the incremental cost to esketamine itself ($16,352), with smaller contributions from physician and medical assistant services ($2,062) and patient time ($2,074), with base case ratios of $237,111/QALY (societal) and $242,496/QALY (healthcare sector). ICER rated the evidence for MDMA-assisted psychotherapy insufficient and used a $10,000 placeholder per course; its micro-costing table lists three 8-hour MDMA sessions (CPT 90837, two therapists) with a cost per session of $1,177 and a total of $7,059; 1.91% of eligible patients could be treated over five years within $735 million per year, and the average annual budget impact per patient was $21,635 in Year one, with cumulative net annual costs of $47,677 per patient in Year five.

Source: [ICER esketamine final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf); [Ross and Soeteman (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7920520/); [Mustafa et al. (2024)](https://icer.org/wp-content/uploads/2024/06/PTSD_Final-Report_For-Publication_06272024.pdf)

<a id="topic-4.1-4"></a>

### Summary: population and burden inputs

The sponsor's funnel counts 50 million U.S. adults with GAD or MDD, 26 million diagnosed, 13 million treated with prescription drugs, and 4.2 million failed by two or more prescription treatments. In the 2022 US National Health and Wellness Survey (N=75,261), adjusted total direct costs were $11,711 for diagnosed and $18,045 for undiagnosed GAD versus $9,190 without GAD, and adjusted indirect costs were $7,507, $7,805, and $6,532 (all comparisons p<0.01). In the 2009 and 2010 Medical Expenditure Panel Survey, annual incremental healthcare expenditure for anxiety disorders was $1657.52 per person, approximately $33.71 billion in total in 2013 US dollars. Among 10,275 patients in a large US health insurance database who started pharmacotherapy for GAD between 2003 and 2007, mean total healthcare costs rose from $4812 before treatment to $7182 during follow-up (p < 0.01). In a MindMed-funded survey of 20 payers covering 130.3 million lives, 40% believed GAD was not a major budgetary concern for their plan, and 70% expected the number of diagnosed individuals seeking reimbursement to increase within 3 years.

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [Duong et al. (2024e)](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2024-4015/143843); [Shirneshan et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24135257/); [Berger et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3266199/); [Duong et al. (2024d)](https://d1io3yog0oux5.cloudfront.net/_1e86c849bdc3b52ea5177f8157ee1069/mindmed/db/2265/21481/pdf/MNMD+AMCP+Nexus+2024+Poster.pdf)

<a id="topic-4.1-5"></a>

### Payer pricing corridor: $30,000 to $75,000 per treatment course, November 2026

> “Commercial Pricing Corridor -- $30,000 to $75,000 per treatment course based on preliminary feedback from health care payers regarding the interventional psychiatry market.”
> “I would just go back to previous statements that I have made about the pricing corridor that payers have advised us they see the pricing corridor here somewhere between the $30 thousand to $75 thousand I think, currently, pay for SPRAVATO.”
> “And as we have payer discussions in the future, we will be able to narrow that corridor, but we feel pretty good about the feedback we have gotten so far.”

Source: [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110)

<a id="topic-4.1-6"></a>

### Annual price range modeled on Spravato as surrogate, January 2026 and May 2026, superseded in November 2026

> “Range is based on Spravato surrogate low dose, low frequency ($28k) to high dose, high frequency ($70k) annually.”
> “Estimated annual pricing (analogous range) $28k to $70k”
> “Market penetration to treat 100,000 patients 0.4%”

Source: [Definium Therapeutics January 2026 corporate presentation (2026)](https://ir.definiumtx.com/sec-filings/all-sec-filings/content/0001193125-26-009854/0001193125-26-009854.pdf)

> “the price of DT120 has not been established.”
> “Range is based on Spravato surrogate low dose, low frequency ($28k) to high dose, high frequency ($70k) annually.”
> “4.2 million patients have been failed by 2 or more treatments”
> “$2 billion revenue opportunity per 1% penetration”
> “Potential Revenue (billions) $2.8B $4.9B $7.0B At $28k annual price At $49k annual price At $70k annual price”

Source: [Definium Therapeutics May 2026 corporate presentation (2026)](https://ir.definiumtx.com/sec-filings/all-sec-filings/content/0001193125-26-229657/dftx-ex99_1.htm)

<a id="topic-4.1-7"></a>

### Revenue opportunity per 100,000 patients treated: November 2026 corporate presentation

> “Modest Adoption Yields Significant Opportunity Given Large and Growing Delivery Ecosystem”
> “Represents approximately half of estimated number of sites in the Spravato® REMS program.”
> “Assumes midpoint of surrogate pricing range for Spravato®. The price of DT120 ODT has not been established.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

| Slide element | Value |
| --- | --- |
| Patients per month | “2” |
| Patients per year | “24” |
| Interventional psychiatry clinics | “~4,000” |
| Patients treated | “100K” |
| Potential gross revenue opportunity | “$5B” |

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-4.1-8"></a>

### Payer insights on pricing and access: sponsor market research, April 2026

> “DT120 Reimbursement Outlook Is Anchored by Spravato® Precedent”
> “Payers reference Spravato as the primary price analog”
> “Payers indicate expectation that FDA-approved psychedelic treatments will be covered”
> “Payers expect to manage use of DT120 with prior authorizations in line with other branded psychiatric products”
> “However, Definium has no intention of marketing the economic merits of its drug.”

Source: [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf)

<a id="topic-4.1-9"></a>

### Session coding and reimbursement: sponsor statement

> “Efficient single-visit model with full-session reimbursement streamlines administrative burden”
> “Required monitoring period for all participants in pivotal studies is 8 hours and requires that participants clear the End of Session Checklist.”
> “Existing coding systems could potentially be applied or be changed for DT120. Reimbursement and coding for DT120 have yet to be established.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-4.1-10"></a>

### Monitoring-session codes for psychedelic medication therapy: CPT Category III codes 0820T to 0822T

| Code | Short description | Time | 2023 Medicare non-facility total RVU |
| --- | --- | --- | --- |
| 0820T | “Continuous in-person monitoring and intervention (e.g. psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other QHP, each hour” | “60 min” | “N/A” |
| +0821T | “Continuous in-person monitoring and intervention (e.g. psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; second physician or other qualified health care professional, concurrent with first physician or other QHP, each hour” | “60 min” | “N/A” |
| +0822T | “Continuous in-person monitoring and intervention (e.g. psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; clinical staff under the direction of a physician or other QHP, concurrent with the first physician or other QHP, each hour” | “60 min” | “N/A” |

Source: [BrainFutures CPT and HCPCS coding guide (2023)](https://www.brainfutures.org/wp-content/uploads/2023/09/A-Guide-to-CPT-and-HCPCS-Codes-for-Psychedelic-Assisted-Therapy_Charts.pdf)

<a id="topic-4.1-11"></a>

### Medicare codes for an observed esketamine session: HCPCS G2082 and G2083

> “To facilitate beneficiary access to treatment for treatment-resistant depression (TRD) as using esketamine, we are creating two new HCPCS G codes, G2082 and G2083, effective January 1, 2020 on an interim final basis.”
> “Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation.”
> “For HCPCS code G2082, we are using a price of $590.02 for the supply input that describes 56 mg (supply code SH109) and for HCPCS code G2083, we are using a price of $885.02 for the supply input describing 84 mg of esketamine (supply code SH110).”

Source: [CMS CY 2020 Physician Fee Schedule final rule (2019)](https://www.federalregister.gov/documents/2019/11/15/2019-24086/medicare-program-cy-2020-revisions-to-payment-policies-under-the-physician-fee-schedule-and-other-changes-to-part)

<a id="topic-4.1-12"></a>

### ICER review of MDMA-assisted psychotherapy for PTSD: evidence rating and placeholder price

> “As such, we conclude that the current publicly-available evidence for MDMA-AP is insufficient”
> “Since there is no publicly available list or net price for MDMA, we relied on an estimate from IPD Analytics suggesting a price for MDMA of approximately $5,000 to $15,000 per course (all three sessions).”
> “We chose the midpoint for the exploratory analysis of $10,000 for all three sessions.”
> “To determine the MDMA-AP non-drug costs, we adopted the micro-costing method of Marseille et al. 2023 and used the Current Procedural Terminology (CPT) codes associated with the MDMA-AP activities.”

Source: [Mustafa et al. (2024)](https://icer.org/wp-content/uploads/2024/06/PTSD_Final-Report_For-Publication_06272024.pdf)

<a id="topic-4.1-13"></a>

### ICER review of MDMA-assisted psychotherapy for PTSD: session costs

| Resource | Resource use (number) | CPT code | Number of therapists | Cost per session | Total |
| --- | --- | --- | --- | --- | --- |
| Psychiatric diagnosis interview examination | “1” | “90792” | “2” | “$219” | “$438” |
| 90 min preparation session | “3” | “90837” | “2” | “$221” | “$1,324” |
| 8-hour MDMA session | “3” | “90837” | “2” | “$1,177” | “$7,059” |
| 90 min integration session | “9” | “90837” | “2” | “$221” | “$3,971” |

Source: [Mustafa et al. (2024)](https://icer.org/wp-content/uploads/2024/06/PTSD_Final-Report_For-Publication_06272024.pdf)

<a id="topic-4.1-14"></a>

### ICER review of MDMA-assisted psychotherapy for PTSD: exploratory budget impact

> “Results showed that at the placeholder price of $10,000 per treatment course, 1.91% of eligible patients could be treated over the span of five years without crossing the ICER potential budget impact threshold of $735 million per year.”
> “At the placeholder price for MDMA-AP, the average annual budget impact per patient was $21,635 in Year one with cumulative net annual costs increasing to $47,677 per patient in Year five.”
> “Stakeholders should be aware, however, that if approved, and if the price of MDMA-AP is similar to analyst estimates, payers could face a significant short-term budget impact.”

Source: [Mustafa et al. (2024)](https://icer.org/wp-content/uploads/2024/06/PTSD_Final-Report_For-Publication_06272024.pdf)

<a id="topic-4.1-15"></a>

### ICER review of esketamine for treatment-resistant depression: cost-effectiveness, observation costs, and budget impact

> “However, at the base-case price of $295 per 28 mg intranasal device, esketamine use results in an incremental cost-effectiveness ratio of approximately $198,000 per QALY compared to no additional treatment, well above the commonly cited cost-effectiveness thresholds.”
> “Since esketamine requires observation of the patient for two hours after each administration, a physician office visit (CPT code 99214) was assigned for each dose, estimated using the Centers for Medicare and Medicaid Services (CMS) Physician Fee Schedule.”
> “As discussed above, we estimated that only 16% of eligible patients could be treated with esketamine at its list price without exceeding ICER’s potential budget impact threshold of $819 million.”
> “Payers should develop mechanisms to adequately compensate clinicians for the expenses associated with monitoring and delivering esketamine within the specification of the REMS program.”

Source: [ICER esketamine final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf)

<a id="topic-4.1-16"></a>

### U.S. cost-effectiveness of esketamine for treatment-resistant depression, including observation costs

> “Our estimate of the total cost of esketamine provision includes costs of the medication itself, physician visits, and medical assistant observation during the two hours after each dose.”
> “This cost increase was driven largely by the cost of esketamine itself ($16,352), with smaller contributions from physician/medical assistant service costs ($2,062) and patient time costs ($2,074).”
> “Base case ICERs were $237,111/QALY (societal) and $242,496/QALY (healthcare sector).”

Source: [Ross and Soeteman (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7920520/)

<a id="topic-4.1-17"></a>

### Cost-effectiveness of first-line drugs for GAD: UK decision model

> “A decision-analytic model in the form of a decision tree was constructed to compare the costs and QALYs of six drugs used as first-line pharmacological treatments in people with GAD (duloxetine, escitalopram, paroxetine, pregabalin, sertraline and venlafaxine extended release [XL]) and 'no pharmacological treatment'.”
> “It also resulted in the lowest costs and highest number of QALYs among all treatment options assessed. Its probability of being the most cost-effective drug reached 75 % at a willingness-to-pay threshold of £20,000 per extra QALY gained.”

Source: [Mavranezouli et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23512146/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
